BC Extra | Sep 17, 2019
Clinical News

Biogen stops Phase II for returned IPF candidate

Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns. Biogen Inc. (NASDAQ:BIIB) had licensed the humanized mAb against...
BC Innovations | Feb 14, 2019
Emerging Company Profile

Indalo: Integral to fibrosis

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo President and CEO Robert...
BC Week In Review | Oct 27, 2017
Clinical News

Biogen reports Phase IIa data for IPF candidate

In its 3Q17 earnings presentation, Biogen Inc. (NASDAQ:BIIB) said BG00011 (STX-100) achieved "proof of biology" in a Phase IIa trial by showing "substantial" downregulation of the transforming growth factor (TGF) beta pathway as measured by...
BioCentury | Oct 13, 2014
Regulation

The lung haul

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will have...
BioCentury | Oct 13, 2014
Regulation

The lung haul

Patients at FDA 's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will have...
BioCentury | Sep 8, 2014
Strategy

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question now...
BC Innovations | Jul 31, 2014
Cover Story

Fresh air for COPD

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth...
BC Innovations | Dec 5, 2013
Cover Story

Targeting fibrotic integrin

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...
BC Week In Review | Jul 30, 2012
Clinical News

STX-100: Phase IIa started

Biogen Idec disclosed in its 2Q12 earnings that in July it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate weekly subcutaneous STX-100 for 8 weeks in 32 IPF patients. The trial includes 4...
BC Innovations | Mar 15, 2012
Targets & Mechanisms

Halofuginone target ID

A U.S. and South Korean research team has identified the molecular target of halofuginone, a small molecule antifibrotic and anti-inflammatory compound. 1 The findings could help guide the design of next-generation halofuginone analogs with improved...
Items per page:
1 - 10 of 24